Goldman Sachs: JD HEALTH (06618) continues to expand its market share, maintains "buy" rating.

Goldman Sachs released a research report stating that JD Health (06618) is expected to have a second-quarter revenue growth that roughly meets market expectations. Despite the relatively lackluster performance during the 618 shopping festival, with support from continued market share gains in core categories, the current forecast predicts a 18% year-on-year increase in second-quarter revenue. Goldman Sachs currently predicts JD Health's second-quarter adjusted operating profit margin to be 7.1%, showing continuous improvement compared to the previous year. The firm also expects growth to accelerate in the second half of the year and maintains a "buy" rating with a target price of HK$65.